Plandai Biotechnology Sets for Battle Against Neurological Diseases by using Nutraceuticals

Plandaí­ Biotechnology, Inc. (OTCQB: PLPL) transforming the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. These extracts are utilized to deliver a new family of drugs to safely and cost effectively treats a plethora of different diseases and conditions. What makes Plandai Biotechnology unique is that they control every aspect of the process from growing these plants and raw materials on their farms in South Africa to producing its patented product Phytofare™
Most recently, Chairman and Chief Executive Officer of Plandai Biotechnology, Roger Duffield, addressed progress with its recently announced subsidiary, Cannabis Biosciences, Inc., in the development and testing of a botanical extract derived from cannabis.

biotech Mr. Duffield stated, “We believe that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson’s, Alzheimer’s, ALS, MS, and post-concussion syndrome. The industry has faced several challenges with bringing cannabis-based therapies that address these issues to market. First, there are legal hurdles to overcome before testing of any kind can even commence. From a pharmacological standpoint, cannabinoids are more tightly regulated that opiates. Second, one of the most active chemicals in cannabis, THC, is also psychoactive when metabolized, which brings with it unwanted effects and social stigma. Finally, administering a clinical dose to target tissues is challenging due to poor bioavailability and metabolization in oral formulations. Smoking enough cannabis to deliver a clinical dose is also impractical.”

“Our research affirms that damage to the CB1 and CB2 brain receptors contributes to several neuron diseases. Cannabis is rich in neuron-beneficial phytocannabinoids including Δ9-THC; however, Δ9-THC taken in an oral preparation converts in the liver to 11-hydroxy metabolite. This new chemical demonstrates high levels of psycho-activity and is significantly less effective in scavenging free radicals. Essentially, you get the psychotropic aspects of the drug with none of the medicinal benefits.”

With this new developed subsidiary Plandai Biotechnology and Cannabis Biosciences plan to use licensed Phytofare™ and Pheroid technologies to produce an FDA approved Phytofare™ cannabinoid complex to fight against numerous neurological diseases. Although there are multiples hurdles that will be faced; the immediate goal is to commence in-vitro testing within six months. Furthermore, within the next twelve months, they hope to commence animal trials in hopes to receive approval for human clinical trials from the FDA.

The comments are closed.